Pipeline › efinopegdutide
efinopegdutide
Not FDA-approved, and in phase 2 development, not authorised in the European Union.
GLP-1/glucagon agonist, SC, from Merck. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- GLP-1/glucagon
- Route
- SC
- Sponsor
- Merck
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 0 (0 in phase 3)
- Participants enrolled
- 0
- Trials with a reporting date
- 0
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-09-21 | Status changed | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) NCT06465186 · Merck Sharp & Dohme LLC | Active, not recruiting → Completed | P2 |
| 2026-09-21 | Results date moved | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) NCT06465186 · Merck Sharp & Dohme LLC | 2026-08-06 → 2026-08-03 | P2 |
| 2026-09-21 | Enrollment changed | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) NCT06465186 · Merck Sharp & Dohme LLC | 80 → 85 participants | P2 |
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2024-12-07 | Comparative Efficacy of Semaglutide Versus Liraglutide or Efinopegdutide on Weight Loss in Obese Patients: A Systematic Review and Meta-Analysis Wen J, How-Volkman C, Truong A, Nadora D, Bernstein EM, Akhtar M, Puglisi J, Frezza E. | Cureus |
| 2023-06-22 | A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, MK-6024 P001 Study Group. | J Hepatol |
Every efinopegdutide trial on file
All 2 registered trials of efinopegdutide, largest first. Each links to its own page and to the registry record.
| Trial | Status | Phase | Participants |
|---|---|---|---|
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) NCT06482112 · Merck Sharp & Dohme LLC | Completed | P2 | 124 |
| A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) NCT06465186 · Merck Sharp & Dohme LLC | Completed | P2 | 85 |